Apellis Pharmaceuticals (NASDAQ:) is navigating headwinds following a negative opinion from the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) regarding the approval of pegcetacoplan, marketed as Syfovre in the United States. This decision has led Mizuho Securities to lower its price target for Apellis from $42 to $39, while maintaining a Neutral rating on the stock.
The EMA's rejection stems from concerns raised during the review process, effectively blocking Apellis from marketing Syfovre within the European Union under current circumstances. Mizuho's analyst, anticipating this outcome, has removed projected EU revenue from their financial model, resulting in a 7% price target decrease. The analyst cites limited potential for stock price appreciation and uncertainty regarding catalysts for significant upward movement.
Financial Performance and Analyst Outlook
Despite the European setback, Apellis reported strong Q2 2024 growth, driven by its drugs SYFOVRE and EMPAVELI. SYFOVRE achieved over $0.5 billion in sales since its launch, with $155 million in net product revenue in Q2 2024 alone. EMPAVELI also contributed substantially with $24.5 million in sales. Analyst firms have reacted to these developments with varied perspectives. While Mizuho has adopted a more cautious stance, BofA Securities revised its price target to $61.00 with a Buy rating, Baird increased the target to $96 with an Outperform rating, and Jefferies set a target of $82.00, also with a Buy rating.
Pegcetacoplan's Potential Beyond Ophthalmology
Pegcetacoplan, also marketed as Empaveli, has demonstrated potential beyond its use in ophthalmology. Recent results from the Phase 3 VALIANT study showcased a significant 68% reduction in proteinuria, a marker of kidney damage, in patients with two rare kidney diseases. This finding suggests a broader therapeutic application for pegcetacoplan in treating complement-mediated diseases.
InvestingPro Insights
According to InvestingPro data, Apellis has a market capitalization of $4.47 billion. The company experienced a robust revenue growth of 240.74% in the last twelve months as of Q2 2024. However, analysts are not optimistic about the company's profitability in the short term, reflected in a negative price-to-earnings (P/E) ratio of -13.58. InvestingPro Tips indicate that while Apellis operates with a moderate level of debt and its liquid assets exceed short-term obligations, the company is not expected to be profitable this year. The stock is trading at a high Price/Book multiple of 16.92, and six analysts have revised their earnings downwards for the upcoming period, signaling caution regarding the company's near-term earnings potential.
